Skip to content

Exploration of clinical application value of HFNC in patients with end-stage lung cancer: a medical records based study

Exploration of clinical application value of HFNC in patients with end-stage lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034448
Enrollment
Unknown
Registered
2020-07-05
Start date
2020-07-10
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

COT:COT

Sponsors

First People's Hospital of Chongqing Liangjiang New Area
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Pathological or cytological diagnosis of lung cancer patients; 2. PS >=2 points; 3. During the hospitalization, he did not receive radiotherapy, immunotherapy and targeted therapy related to lung cancer; 4. Complicated respiratory failure: (1) Oxygenation index <300 under oxygen therapy; (2) PaO2 <60 mmHg under air inhalation; if blood gas analysis is not available, SPO2 <90% can be substituted under air inhalation).

Exclusion criteria

Exclusion criteria: 1. Age 500ml; 4. Cardiogenic pulmonary edema; 5. Intubation or non-invasive positive pressure ventilation has been given; 6. Pneumothorax; 7. Incomplete data; 8. Death within 2 hours of admission; 9. HFNC or COT use less than 2 hours.

Design outcomes

Primary

MeasureTime frame
Treatment failure rate;

Secondary

MeasureTime frame
mortality rate;Blood gas;breath rate;heartrate;Ventilator time;Adverse event rate;

Countries

China

Contacts

Public ContactWang Yang

First People's Hospital of Chongqing Liangjiang New Area

366446516@qq.com+86 023 61103649

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026